Association between Retinoicacid receptor-βhypermethylation and NSCLC risk: a meta-analysis and literature review

// Yan Li 1 , De-guo Lu 2 , Ying-mei Ma 2 and Hongxiang Liu 3 1 Department of Respiratory, The Ninth People’s Hospital of Chongqing, Chongqing, P. R. China 2 Clinical Laboratory, Linyi People’s Hospital, Linyi, Shandong, P. R. China 3 Department of Cardiothoracic Surgery, Southwest Hospital, Third Military Medical University, Chongqing, P.R. China Correspondence to: Hongxiang Liu, email: // Keywords : RARβ, methylation, lung cancer, meta-analysis, tumor suppressor gene Received : September 06, 2016 Accepted : December 12, 2016 Published : December 19, 2016 Abstract Emerging evidence indicates that Retinoic acid receptor- β ( RARβ) is a tumor suppressor in many types of tumor. However, whether or not RARβ is a risk factor and is correlated to clinicopathological characteristics of non-small cell lung cancer (NSCLC) remains unclear. In this report, we performed a meta-analysis to determine the effects of RARβ hypermethylation on the incidence of NSCLC and clinicopathological characteristics in human NSCLC patients. Final valuation and analysis of 1780 cancer patients from 16 eligible studies was performed. RARβ hypermethylation was found to be significantly higher in NSCLC than in normal lung tissue, the pooled OR from 7 studies including 646 NSCLC and 580 normal lung tissues, OR = 6.05, 95% CI = 3.56-10.25, p